These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38199212)

  • 1. Liquid-liquid phase separation-related lncRNA prognostic signature and ZNF32-AS2 as a novel biomarker in hepatocellular carcinoma.
    Peng W; Li Y; Cheng B; Cao M; Liu L; Yang Y; Bai S; Xiong S; Chen W; Zhao Y
    Comput Biol Med; 2024 Feb; 169():107975. PubMed ID: 38199212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of competing endogenous RNA network identifies a poorly differentiated cancer-specific RNA signature for hepatocellular carcinoma.
    Chen QF; Huang T; Si-Tu QJ; Wu P; Shen L; Li W; Huang Z
    J Cell Biochem; 2020 Mar; 121(3):2303-2317. PubMed ID: 31642123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
    Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
    Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
    Zhao QJ; Zhang J; Xu L; Liu FF
    World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1.
    Wang YG; Wang T; Shi M; Zhai B
    J Exp Clin Cancer Res; 2019 Apr; 38(1):153. PubMed ID: 30971290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The liquid-liquid phase separation signature predicts the prognosis and immunotherapy response in hepatocellular carcinoma.
    Wang Z; Wang G; Zhao P; Sun P
    J Cell Mol Med; 2024 Jul; 28(14):e18446. PubMed ID: 39072983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
    Xu Q; Wang Y; Huang W
    Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
    Yan J; Zhou C; Guo K; Li Q; Wang Z
    J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of an immune-related ceRNA network in identifying a novel lncRNA signature as a prognostic biomarker for hepatocellular carcinoma.
    Chen R; Chen Y; Huang W; Zhao Y; Luo W; Lin J; Wang Z; Yang J
    Aging (Albany NY); 2021 Jul; 13(13):17607-17628. PubMed ID: 34237706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA XXYLT1-AS2 promotes tumor progression via autophagy inhibition through ubiquitinated degradation of TFEB in hepatocellular carcinoma.
    Li X; Wu Y; Wang P; Li Y; Gu J; Zhang Y; Yan S; Hu P
    Clin Transl Oncol; 2024 Mar; 26(3):698-708. PubMed ID: 37540409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOX Antisense lincRNA HOXA-AS2 Promotes Tumorigenesis of Hepatocellular Carcinoma.
    Wang F; Yang H; Deng Z; Su Y; Fang Q; Yin Z
    Cell Physiol Biochem; 2016; 40(1-2):287-296. PubMed ID: 27855366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma.
    He H; Wang Y; Ye P; Yi D; Cheng Y; Tang H; Zhu Z; Wang X; Jin S
    J Exp Clin Cancer Res; 2020 Aug; 39(1):159. PubMed ID: 32795316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
    Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
    BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Novel N7-Methylguanosine-Related LncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma and Experiment Verification.
    Yang C; Zhang L; Hao X; Tang M; Zhou B; Hou J
    Curr Oncol; 2022 Dec; 30(1):430-448. PubMed ID: 36661684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
    Li R; Jin C; Zhao W; Liang R; Xiong H
    BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis identifies a long non-coding RNAs-messenger RNAs signature for prediction of prognosis in hepatitis B virus-hepatocellular carcinoma patients.
    Bai Z; Li H; Li C; Sheng C; Zhao X
    Medicine (Baltimore); 2020 Oct; 99(40):e21503. PubMed ID: 33019382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.